IBI362
Phase 3Small molecule
Innovent Biologics (Suzhou) Co. Ltd.IBI362 is one of 156 small molecule programs targeting Obstructive Sleep Apnea. It is currently in Phase 3.
5
Indications
20
Total Trials
9
Active Trials
155
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
176 competitors in Obesity
#DrugCompanyPhaseTrials
1Vivia
SSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Phase 3
IBI362
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
HRS9531
FFujian Shengdi Pharmaceutical Co., Ltd.
Phase 3
Cagrisema
Novo NordiskPhase 3
Eloralintide
Eli LillyPhase 3
PF-08653944
PfizerPhase 3
Efsubaglutide Alfa
SShanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Phase 3
Semaglutide or Tirzepatide
NNational and Kapodistrian University of Athens
Phase 3
Actemra
RochePreclinical
Avapro
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Overweight4 trials
Show 1 more trial
Obesity4 trials
Type 2 Diabetes4 trials
Overweight or Obese1 trial
Fatty Liver Disease1 trial
6 more indications
Obstructive Sleep Apnea1 trial
Metabolic Dysfunction-Associated Steatohepatitis (MASH)1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IBI362. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details